SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Lindblad S)
 

Search: WFRF:(Lindblad S) > Incidence of SARS-C...

  • Naehrlich, L. (author)

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • Elsevier BV,2021

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/308047
  • https://gup.ub.gu.se/publication/308047URI
  • https://doi.org/10.1016/j.jcf.2021.03.017DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:147418919URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). Methods: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. Results: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/10 0 0 pwCF. Incidence was higher in lung-transplanted patients (n = 23) versus non transplanted patients (n = 107) (8.43 versus 2.36 cases/10 0 0). Incidence was higher in pwCF versus the age-matched general population in the age groups < 15, 15-24, and 25-49 years (p < 0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p = 0.133). Conclusions: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination. (c) 2021 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Orenti, A. (author)
  • Dunlevy, F. (author)
  • Kasmi, I. (author)
  • Harutyunyan, S. (author)
  • Pfleger, A. (author)
  • Keegan, S. (author)
  • Daneau, G. (author)
  • Petrova, G. (author)
  • Tjesic-Drinkovic, D. (author)
  • Yiallouros, P. (author)
  • Bilkova, A. (author)
  • Olesen, H. V. (author)
  • Burgel, P. R. (author)
  • Parulava, T. (author)
  • Diamantea, F. (author)
  • Parniczky, A. (author)
  • McKone, E. F. (author)
  • Mei-Zahav, M. (author)
  • Salvatore, M. (author)
  • Colombo, C. (author)
  • Aleksejeva, E. (author)
  • Malakauskas, K. (author)
  • Schlesser, M. (author)
  • Fustik, S. (author)
  • Turcu, O. (author)
  • Zomer-van Ommen, D. (author)
  • Wathne, A. S. (author)
  • Wozniacki, L. (author)
  • Pereira, L. (author)
  • Pop, L. (author)
  • Kashirskaya, N. (author)
  • Rodic, M. (author)
  • Kayserova, H. (author)
  • Krivecs, U. (author)
  • Mondejar-Lopez, P. (author)
  • de Monsterol, I. (author)
  • Dogru, D. (author)
  • Makukh, H. (author)
  • Cosgriff, R. (author)
  • van Koningsbruggen-Rietschel, S. (author)
  • Jung, A. D. (author)
  • Bobrovnichy, V. (author)
  • Bambir, I. (author)
  • Vukic, A. D. (author)
  • Drevinek, P. (author)
  • Macek, M. (author)
  • Corvol, H. (author)
  • Lemonnier-Videau, L. (author)
  • Hatziagorou, E. (author)
  • Fletcher, G. (author)
  • Padoan, R. (author)
  • Gulmans, V. (author)
  • Bakkeheim, E. (author)
  • Kondratyeva, E. (author)
  • Amelina, E. (author)
  • Zhekaite, E. (author)
  • Simonova, O. (author)
  • Pastor-Vivero, M. D. (author)
  • Lindblad, Anders,1955Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics(Swepub:gu)xlinaq (author)
  • Gokdemir, Y. (author)
  • Pekcan, S. (author)
  • Brownlee, K. (author)
  • McClenaghan, E. (author)
  • Carr, S. (author)
  • Lammertyn, E. (author)
  • Zolin, A. (author)
  • Fox, A. (author)
  • Krasnyk, M. (author)
  • Van Rens, J. (author)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för pediatrik (creator_code:org_t)

Related titles

  • In:Journal of Cystic Fibrosis: Elsevier BV20:4, s. 566-5771569-1993
  • In:Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society: Elsevier BV20:4, s. 566-5771873-5010

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view